BACKGROUND A number of different measures can be used within cost-utility analyses, we compared results according to both the EQ-5D and SF-6D. METHODS A randomized trial was conducted to compare 4 options for people with knee pain. Over the 2 year trial period, the change in cost to health-service was estimated, and both the EQ-5D and SF-6D were used to estimate the change in quality-adjusted...

To aid priority setting in prevention, the Assessing Cost-Effectiveness in Prevention Project (ACE-Prevention) applies standardised evaluation methods to assess the cost-effectiveness of 100 to 150 preventive interventions, taking predominantly a health sector perspective. This information is intended to help decision makers move resources from less efficient current practices to more efficient...

the aim of this study is to assess cost-effectiveness of infliximab, compared with conventional treatments in patients with moderate to severe ulcerative colitis (uc) in iran. we developed an analytical decision model with a 5-year-time horizon to follow up 1000 hypothetical patients, in order to estimate treatment costs and outcomes. hypothetical patients, were individuals with moderate to sev...

PURPOSE The aim of this paper is to highlight the contributions that complementary efficacy, effectiveness, and cost-effectiveness studies can make to assessing the outcomes of assistive technology interventions for enhancing mobility. METHOD The terms, 'assistive technology outcomes research' and 'assistive technology interventions', are defined. Several bases are examined for the shortage o...

A retrospective survey, based on a standardized questionnaire sent to qualified public health experts in tuberculosis in 50 European countries, was carried out to evaluate the following: concordance between national vaccination programmes and WHO recommendations on BCG vaccination for prevention of tuberculosis; relation between BCG vaccination and revaccination policy and the tuberculosis epid...

Methods of economic evaluation, especially cost-effectiveness analysis and cost-benefit analysis, are widely used to examine new healthcare technologies. However, few economic evaluations of pharmacogenomics have been conducted, and pharmacogenomic researchers may be unfamiliar with how to review or conduct these analyses. This review provides an overview of the methods of economic evaluation a...

human papilloma virus (hpv) vaccine recently has been added to the iran drug list, decision makers need information beyond that available from rcts to recommend funding for this vaccination program to add it to the national immunization program in iran. modeling and economic studies have addressed some of those information needs in foreign countries. in order to determine the long term benefit ...

These modes of analysis [cost-effectiveness and cost-benefit] are neither good for nothing nor good for everything, and one cannot speak of them as wholly good or bad. It is much more useful to try to specify some conditions under which they would or would not be helpful for various purposes.